Nicușor Florin Bîgiu

Nicușor Florin Bîgiu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Plants
Verified
Journal Article
Open access
PDF file
MMMahwish Mahwish
Mahwish Mahwish
FSFarhan Saeed
Farhan Saeed
MSMuhammad Tauseef Sultan
Muhammad Tauseef Sultan
ARAyesha Riaz
Ayesha Riaz
SASagheer Ahmed
Sagheer Ahmed
RMRosana Mihaela Manea
Rosana Mihaela Manea
Natural products are gaining clinical significance in modern day health care systems to prevent diseases. Bitter melon, a health promoting vegetable, is traditionally used for medical nutrition therapy to cure diabetes but to reap maximum health claims, vigilant control of its substances in diet is crucial as part of curative action for effective diabetes management. In the present research, first phase focused on detection of key bioactive components, i.e., charantin and vicine in different parts of its fruit. In the second phase, normal and hyperglycemic Sprague Dawley rats were fed on skin, flesh and whole fruit of bitter melon at 150 and 300 mg/kg body weight and assessed for diabetes prophylaxis and treatment. The highest amount of charantin (0.16 ± 0.02 mg/g) was recorded in flesh while vicine was present in abundance in whole fruit (0.21 ± 0.01 μg/100 g). In normal rats, bitter melon supplementation was helpful in managing the onset of diabetes. Hyperglycemic rats showed diabetic complications including polydipsia, polyuria, glycosuria, renal hypertrophy and increased glomerular filtration rate. However, bitter melon consumption showed significant improvements in these parameters. The most potent dose was 300 mg/kg whole fruit that resulted in 31.64% lowering of blood glucose level and 27.35% increase in insulin level in hyperglycemic rats.

29 August 2017 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
ATAndreea Teodorescu
Andreea Teodorescu
PIPetru Ifteni
Petru Ifteni
Marius MogaMarius Moga
Marius Moga
VBVictoria Burtea
Victoria Burtea
NBNicușor Florin Bîgiu
Nicușor Florin Bîgiu
The choice of antipsychotic treatment during pregnancy remains controversial, mainly due to a lack of exposure and outcome data. Randomized clinical trials are practically impossible due to ethical reasons. Our reports describe three cases of closely monitored female patients with schizophrenia who were treated with olanzapine during pregnancy. The novelty of reports is that all patients were previously treated with olanzapine long acting injectable (LAI) for an average period of 3.8 years. During the LAI treatment period they were in remission and then refused to continue with LAI mainly due to treatment modality (injectable administration). The patients were relatively young, diagnosed with schizophrenia and were previously successfully treated with long acting injectable. The women were pregnant for the first time. In two cases, the patients had become pregnant during remission and they continued treatment with oral olanzapine. In the third case, olanzapine treatment was initiated during admission for a relapse. There are no controlled studies for the use of olanzapine therapy in pregnant women. More studies are needed to determine the effects of antipsychotics, including olanzapine, on pregnant women and the developing fetus. Schizophrenia relapse during pregnancy may expose the mother and the fetus to high risk if olanzapine is stopped. It is important to assess the risks and benefits of treating pregnant or breastfeeding women with antipsychotics, and weigh these against possible risks of anomalies and developmental problems to the fetus or child.

6 October 2015
Verified
Journal Article
Closed access
MMM A Moga
M A Moga
CAC A Arvatescu
C A Arvatescu
GPG C Pratilas
G C Pratilas
NBNicușor Florin Bîgiu
Nicușor Florin Bîgiu
KDK Dinas
K Dinas
VBV Burtea
V Burtea

10 April 2016 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Closed access
MMM. A. Moga
M. A. Moga
ADA. Daniilidis
A. Daniilidis
NBNicușor Florin Bîgiu
Nicușor Florin Bîgiu
CAC. Andrei
C. Andrei
KDK. Dinas
K. Dinas
DFD. G. Festila
D. G. Festila
Purpose: To report a rare case of ganglioneuroblastoma encountered rarely in adults, especially during pregnancy. Materials and Methods: The authors present a case of ganglioneuroblastoma relapse during the third trimester of pregnancy in a patient previously treated for ganglioneuroblastoma who had a eight-year disease-free interval. Late manifestation of neurological symptoms (vestibular syndrome, nystagmus, slightly right motor deficit) was perhaps influenced by the hormonal pregnancy effects. In this case the option was for caesarean section under general anesthesia at 36 weeks. Results: Based on MRI result, the neurosurgical consultation stated the need of postpartum brain tumor excision. Recovery of the mother was complication-free with persistent, constant postoperative neurological symptoms. It resulted in a healthy newborn, not requiring special follow-up. Conclusions: Pregnancy and brain tumor have mutual negative effect on the patient. Therapeutic management in this case was a medical dilemma regarding mode setting and timing of delivery, taking into account the maternal-fetal risk-benefit.